Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway

Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway

As a sodium-glucose transporter 2 inhibitor (SGLT2i), the cardioprotective benefits of Dapagliflozin (DAPA) are now widely appreciated. However, the underlying mechanism of DAPA on angiotensin II (Ang II)-induced myocardial hypertrophy has never been evaluated. In this study, we not only investigate...

Full description

Bibliographic Details
Main Authors: Jingyao Yang, Long Li, Xiaoxiao Zheng, Zhaoyang Lu, Hua Zhou
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Apoptosis
Myocardial hypertrophy
Cardiac fibrosis
SIRT1/HIF-1α pathway
Dapagliflozin
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223009162

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223009162

Similar Items